Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Acquired by Geode Capital Management LLC

Geode Capital Management LLC lifted its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 9.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 998,654 shares of the specialty pharmaceutical company’s stock after purchasing an additional 88,386 shares during the quarter. Geode Capital Management LLC owned 1.63% of Jazz Pharmaceuticals worth $177,204,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Berman Capital Advisors LLC grew its stake in Jazz Pharmaceuticals by 421.1% in the 2nd quarter. Berman Capital Advisors LLC now owns 198 shares of the specialty pharmaceutical company’s stock valued at $35,000 after acquiring an additional 160 shares during the period. Advisory Services Network LLC acquired a new stake in Jazz Pharmaceuticals in the 2nd quarter valued at $37,000. Mark Sheptoff Financial Planning LLC acquired a new stake in Jazz Pharmaceuticals in the 2nd quarter valued at $38,000. Benjamin F. Edwards & Company Inc. grew its stake in Jazz Pharmaceuticals by 29.1% in the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 297 shares of the specialty pharmaceutical company’s stock valued at $49,000 after acquiring an additional 67 shares during the period. Finally, Trustcore Financial Services LLC grew its stake in Jazz Pharmaceuticals by 82.6% in the 2nd quarter. Trustcore Financial Services LLC now owns 347 shares of the specialty pharmaceutical company’s stock valued at $62,000 after acquiring an additional 157 shares during the period. 92.69% of the stock is currently owned by institutional investors and hedge funds.

JAZZ has been the topic of a number of research analyst reports. Royal Bank of Canada lifted their price target on shares of Jazz Pharmaceuticals from $190.00 to $216.00 and gave the company an “outperform” rating in a research note on Friday, July 23rd. SVB Leerink restated a “buy” rating on shares of Jazz Pharmaceuticals in a report on Thursday, July 22nd. Morgan Stanley decreased their price objective on Jazz Pharmaceuticals from $176.00 to $174.00 and set an “equal weight” rating on the stock in a report on Friday, October 8th. TheStreet lowered Jazz Pharmaceuticals from a “b” rating to a “c” rating in a report on Monday, August 9th. Finally, Needham & Company LLC started coverage on Jazz Pharmaceuticals in a report on Wednesday, September 22nd. They issued a “buy” rating and a $220.00 price objective on the stock. Two analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $206.50.

NASDAQ JAZZ opened at $134.59 on Thursday. The firm has a market cap of $8.26 billion, a PE ratio of 141.68, a P/E/G ratio of 0.76 and a beta of 0.97. Jazz Pharmaceuticals plc has a 52 week low of $126.01 and a 52 week high of $189.00. The business’s fifty day simple moving average is $135.64 and its 200-day simple moving average is $160.46. The company has a quick ratio of 1.93, a current ratio of 3.35 and a debt-to-equity ratio of 1.57.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, August 3rd. The specialty pharmaceutical company reported $3.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.08 by $0.82. The firm had revenue of $751.81 million for the quarter, compared to analyst estimates of $743.19 million. Jazz Pharmaceuticals had a net margin of 1.53% and a return on equity of 22.00%. Research analysts expect that Jazz Pharmaceuticals plc will post 11.87 EPS for the current year.

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,750 shares of Jazz Pharmaceuticals stock in a transaction dated Monday, August 2nd. The stock was sold at an average price of $169.98, for a total value of $297,465.00. Following the completion of the transaction, the chief executive officer now directly owns 307,388 shares of the company’s stock, valued at approximately $52,249,812.24. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Elmar Schnee sold 1,632 shares of Jazz Pharmaceuticals stock in a transaction dated Thursday, August 5th. The shares were sold at an average price of $154.00, for a total value of $251,328.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 10,200 shares of company stock worth $1,437,379. 4.30% of the stock is owned by insiders.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: Xyrem, Xywav, Sunosi, Erwinaze, Vyxeos, Defitelio, and Zepzelca.

Recommended Story: How do candlesticks reflect price movement?

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals plc (NASDAQ:JAZZ).

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.